This research investigates how humoral immunity determines the success of immune checkpoint blockade (ICB) therapy in cancer patients. By analyzing various datasets, the authors found that patients who respond well to treatment exhibit a significant expansion of IgG1-secreting plasma cells and antibodies targeting cancer-testis antigens. These specific immune cells infiltrate the tumor and create a highly immunogenic environment through coordinated signaling with T cells and macrophages. In contrast, non-responders tend to accumulate dysfunctional memory B cells and lack this specialized IgG1 activity. The study suggests that tracking IgG1 plasma cell signatures can serve as a vital predictive biomarker for immunotherapy outcomes. Ultimately, these findings offer a new strategy for improving cancer treatment by specifically stimulating B cell differentiation into effective antibody-producing cells.

References:

• Gonzalez-Kozlova E, Sweeney R, Figueiredo I, et al. Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade[J]. Nature Medicine, 2026: 1-14.